CCL21 and non-small cell lung carcinoma: (71) conducted a clinical study to evaluate the safety, efficacy, and anti-tumor immune response in patients with stage IIIB/IV NSCLC who received intratumoral vaccination with autologous DCs transduced with an adenoviral vector expressing CCL21 gene (Ad-CCL21-DC).